Genetic evidence supports causal effect for diastolic BP on benign prostatic hyperplasia
Aug 03, 2023
The risk effect of diastolic blood pressure on benign prostatic hyperplasia persists after conditioning with waist circumference.
Tech can help measure paces for seniors with heart issues, but doesn’t supply the final step: long-term...
By
Aaron Dorman
Sep 28, 2023
New studies indicate devices can help residents stay fit and avoid heart emergencies, but motivation may need to come from caregivers.
High coffee intake linked to CVD mortality in severe hypertension
Dec 21, 2022
“These findings may support the assertion that people with severe high blood pressure should avoid drinking excessive coffee,” a coauthor said in a statement.
Certain antihypertensive agents may aid cognition in elderly
Jun 21, 2021
Memory recall is better for up to three years with blood-brain barrier-crossing renin-angiotensin drugs versus nonpenetrant counterparts.
Task force: Statins may not benefit those 76+
By
Lois A. Bowers
Nov 13, 2016
Your residents may be interested to know that not enough evidence exists to recommend statins to prevent heart disease for people aged more than 75 years, according to a final recommendation statement...
Use of antihypertensive drugs may increase risk for psoriasis
Oct 06, 2021
A meta-analysis shows that ACE inhibitors, ß-blockers, calcium-channel blockers and thiazide diuretics are associated with an increased risk for psoriasis.
Being a victim of fraud may increase blood pressure in seniors
Aug 04, 2022
Incident fraud victimization is tied to worse blood pressure metrics, particularly among men.
Higher flavonoid intake may lower systolic blood pressure
Aug 23, 2021
Higher consumption of berries and red wine was linked to lower systolic blood pressure. The association was partly explained by microbial factors.
Greater variety of dietary protein may lower risk for hypertension
Mar 10, 2022
Protein consumed in moderate amounts from various sources was linked to a lower risk for developing hypertension.
Monoclonal antibody therapy may cut COVID-19 hospitalizations
Aug 31, 2021
Lower hospitalization rates were seen at 14, 21 and 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab.